Extended release midodrine hydrochloride compositions and methods of use
This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, or a pharmaceutically acceptable salt thereof, that can be administered to a human subject in need thereof. The disclosure also provides pharmaceutical compositions for treatment of orthostatic hypotension that can be administered once or twice a day.
1. A pharmaceutical composition comprising:
a first release portion comprising an active agent in a range of about 20% to about 40% (w/w) of a total amount of the active agent in the composition;
a second release portion comprising the active agent in a range of about 60% to about 80% (w/w) of the total amount of the active agent in the composition; and
a rate controlling agent, wherein the rate controlling agent is selected from the group consisting of a water-soluble excipient, a water-insoluble excipient, a water permeable excipient, and a combination thereof, and wherein the rate controlling agent is present in a weight ratio of the active agent in the second release portion of the composition to the rate controlling agent of about 1:1 to about 1:30 (w/w);
wherein the in vitro release rate of the active agent, measured by an in vitro dissolution test comprises (i) a first release that is relatively fast and (ii) a second release, wherein the second release does not include a second rise in release rate that takes place about 5 hours to about 10 hours after start of the in vitro dissolution test,
wherein the active agent is selected from the group consisting of midodrine, a pharmaceutically acceptable salt of midodrine, desglymidodrine, a pharmaceutically acceptable salt of desglymidodrine, and any combination thereof; and
wherein the second release comprises a second rise in release rate that takes place about 2 to about 4.5 hours after start of the in vitro dissolution test.
2. The pharmaceutical composition of claim 1 , further comprising:
(iii) a third release which includes a third rise in release rate that takes place about 5 hours to about 8 hours after start of the in vitro dissolution test, and
wherein the active agent is selected from the group consisting of midodrine, a pharmaceutically acceptable salt of midodrine, desglymidodrine, a pharmaceutically acceptable salt of desglymidodrine, and any combination thereof.
3. The pharmaceutical composition of claim 1 , wherein the first release portion comprises about 1.5 mg to about 45 mg of active agent and an excipient, wherein the active agent is present in an amount of about 2% to about 40% of the total weight of the first release portion; and the second release portion comprises about 3.5 mg to about 105 mg of active agent and a rate controlling agent, wherein the active agent is present in an amount of about 2% to about 20% of the total weight of the second release portion, and the amount of active agent in the second release portion to the amount of rate controlling agent is a ratio of about 1:1 to about 1:30 (w/w), and the total amount of the active agent is about 5 mg to about 150 mg.
4. The pharmaceutical composition of claim 1 , wherein substantially all of the active agent in the first release portion is released within about 1 hour after administration of the pharmaceutical composition to a subject; and substantially all of the active agent in the second release portion is released over a period of time between about 1 hour after administration of the composition to the subject and up to about 16 hours after administration of the composition to a subject.
5. The pharmaceutical composition of claim 1 , wherein the in vitro dissolution test was performed with USP Apparatus I (baskets) at 100 rpm in 900 mL at 37° C. for 0-2 hours in 0.1N HCl (pH 1.2); for 2-4 hours in acetate buffer (pH 4.5); and for 4-16 hours or 4-12 hours in phosphate buffer (pH 6.8).
6. The pharmaceutical composition of claim 1 , wherein at least about 20% of the total amount of active agent in the composition is released within about 1 hour and at least about 80% of the total amount of active agent in the composition is released within about 12 hours after the start of an in vitro dissolution test.
7. The pharmaceutical composition of claim 1 , wherein the active agent is present in a total amount of about 7.5 mg to about 120 mg.
8. The pharmaceutical composition of claim 1 , wherein the in vitro release rate of the active agent during the second release phase is slower compared to the in vitro release rate of the active agent released during the first release phase.
9. The pharmaceutical composition of claim 1 , wherein the rate controlling agent is present in a weight ratio of the active agent in the second release portion of the composition to the rate controlling agent of about 1:5 to about 1:15 (w/w).
10. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a multilayer tablet, or a capsule comprising a plurality of fast release pellets and a plurality of extended release pellets.
11. The pharmaceutical composition of claim 1 , wherein the active agent is present in the first release portion in an amount of about 1.5 mg to about 45 mg, and in the second release portion in an amount of about 3.5 mg to about 105 mg.
12. The pharmaceutical composition of claim 1 , wherein administration of the pharmaceutical composition to a subject provides (i) a relatively fast peak plasma concentration reaching at least about 12 ng/ml of desglymidodrine within about 1 hour and (ii) a plasma concentration of desglymidodrine of at least about 7 ng/ml or at least about 10 ng/ml for at least about 8 hours or at least about 10 hours.
13. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a multi-layer tablet, a capsule, or suspension, wherein:
the first release portion comprises an amount of the active agent in the range of about 1.5 mg to 45 mg; the second release portion comprises an amount of the active agent in the range of about 3.5 mg to about 105 mg; and
the first release portion releases at least about 20% to about 40% w/w of the total amount of the active agent in the tablet, capsule, or suspension within about 1 hour and the second release portion releases the remaining total amount of the active agent in the tablet, capsule, or suspension at a slower rate than the release rate of the first release portion in an in vitro dissolution test.
14. The pharmaceutical composition of claim 13 , wherein the second release portion comprises a rate controlling agent, wherein the rate controlling agent is selected from the group consisting of a water soluble excipient, a water-insoluble excipient, a water permeable excipient, and a combination thereof, and wherein the amount of active agent in the second release portion to the amount of rate controlling agent is a ratio of about 1:1 to about 1:30 (w/w), optionally about 1:5 to about 1:15 (w/w).
15. The pharmaceutical composition of claim 13 , wherein the second release portion further comprises a-rate controlling agent comprises comprising a methacrylic acid copolymer and a fatty acid ester.
16. A method for treating orthostatic hypotension or postural orthostatic tachycardia syndrome (POTS) in a subject comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.
17. The method of claim 16 , wherein a single dose of the pharmaceutical composition comprises about 10% to 70% more than the total amount of active agent in three 2.5 mg, 5 mg, or 10 mg immediate release tablets.
18. A kit comprising:
a first formulation and a second formulation, wherein the first and second formulations comprise the same active agent or different active agents, and
the first formulation comprises a pharmaceutical composition of claim 1 .